cd47 polyclonal antibody (Proteintech)
Structured Review

Cd47 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 78 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd47 polyclonal antibody/product/Proteintech
Average 95 stars, based on 78 article reviews
Images
1) Product Images from "Targeted biomimetic fusogenic liposome enhances tumor accumulation, penetration, and therapeutic efficacy of siRNA therapeutics"
Article Title: Targeted biomimetic fusogenic liposome enhances tumor accumulation, penetration, and therapeutic efficacy of siRNA therapeutics
Journal: Materials Today Bio
doi: 10.1016/j.mtbio.2025.102414
Figure Legend Snippet: Antitumor effects of CRPIL/siCD47 complexes. (a) Expression of CD4 7 mRNA in 4T1 cells after different treatments. (b) Schematic illustration of in vitro phagocytosis assay. (c–d) Fluorescence microscope images and quantification of phagocytosis efficiency of J774A.1 cells against 4T1 cells. (e) Schematic illustration of in vitro tumor cell inhibition assay. (f) Cellular viability of 4T1 cells following various treatments in co-culture with J774A.1 macrophages. (g) Schematic illustration of siRNA treatment schedule. (h) Changes in tumor volumes during the treatment. (i–j) Dissected tumors and their average weights after treatment. (k) CD47 protein expression in tumor tissues across treatment groups. (l) Infiltration of CD86 + M1 macrophages in tumors following different treatments.
Techniques Used: Expressing, In Vitro, Phagocytosis Assay, Fluorescence, Microscopy, Inhibition, Co-Culture Assay
Figure Legend Snippet: Antitumor effects of CRPIL/siCD47/siPLK1 complexes. (a). Expression of CD4 7 mRNA and PLK1 mRNA in 4T1 cells after different treatments. (b) The phagocytosis efficiency of J774A.1 cells against 4T1 cells after different treatments. (c) Schematic illustration of treatment schedule. (d) Changes in tumor volumes during the treatment. (e–f) Photographs of dissected tumors and average tumor weights at the end of the treatment. (g) Expression of CD47 and PLK1 proteins in tumor tissues after different treatments. (h) Representative images of hematoxylin and eosin-stained, TUNEL-stained and calreticulin (CRT)-stained tumor tissues on day 14.
Techniques Used: Expressing, Staining, TUNEL Assay

![<t>CD47</t> expression in striatal neurons of R6/2 mice. Confocal laser scanning microscopy images of double-label immunofluorescence for CD47 (visualized in red fluorescence) and the Nissl-like fluorescent marker Neurotrace (visualized in green fluorescence). (A–D) Images show the expression pattern of CD47 in the striatum of 5 and 13 weeks-old wild-type mice and in 5 and 13 weeks-old R6/2 mice. (E,F) Detail of cytoplasmic membrane CD47 expression in 13 weeks-old Wt mice. In 13 weeks-old R6/2 mice CD47 is lower due to cell death process (G) Histogram shows CD47 intensity quantification which is significantly decreased in the striatal neurons of 13 weeks-old R6/2 mice [Genotype effect F (1,153) = 11.97, *** P = 0.0007]. (H,I) Tukey’s multiple comparisons analysis revealed a significant protein decrease of striatal neuronal CD47, as evaluated by western blotting in R6/2 mice [Genotype effect F (1,20) = 8.667, ** P = 0.0080; Time effect F (1,20) = 5.802, ** P = 0.0258; Genotype X Time Interaction F (1,20) = 37.89, *** P < 0,0001].](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_2295/pmc10912295/pmc10912295__fncel-18-1360066-g001.jpg)
